Form 4 Filing for Avalo Therapeutics, Inc.

Jonathan Goldman, a director at Avalo Therapeutics, Inc. (AVTX), reported a transaction on March 28, 2026. The filing details the conversion of 3,166 Restricted Stock Units (RSUs) into 3,166 shares of Common Stock. This conversion was part of a grant received on August 13, 2024, with vesting scheduled in three tranches on March 28, 2025, March 28, 2026, and March 28, 2027. The RSUs convert to common stock on a one-for-one basis. Following this transaction, Goldman directly owns 3,166 shares of common stock. The transaction code M indicates a merger or conversion, and the acquired/disposed code A signifies acquisition.